Showing results (1-10 of 40) with videos related to
Sort By:
Pageof 4
Seminars in Nuclear Medicine|December 18, 2025
Assessing therapeutic response to Radium-223Caroline Torricelli, Ludmila Almeida, Elba EtchebeherePharmaceuticals (Basel, Switzerland)|November 27, 2024
Theranostics Nuclear Medicine in Prostate CancerHelena Lima, Marina Etchebehere, Mateos Bogoni, et al.Seminars in Nuclear Medicine|March 17, 2020
Radium-223 as an Approved Modality for Treatment of Bone MetastasesAna Emília Brito, Elba EtchebehereSeminars in Nuclear Medicine|October 11, 2024
18F-Fluoride PET/CT-UpdatesEllen Nogueira-Lima, Thiago Alves, Elba EtchebehereCurrent Radiopharmaceuticals|November 3, 2016
Gallium-68 in Medical ImagingLucia Martiniova, Louis De Palatis, Elba Etchebehere, et al.Clinical Nuclear Medicine|July 14, 2020
Typical Acute Traumatic Fracture Healing in an 83-Year-Old Man Undergoing 223Ra Treatment for Prostatic Cancer Bone MetastasesThaís Minekawa, Mariana Lima, André Moraes, et al.European Journal of Nuclear Medicine and Molecular Imaging|June 2, 2017
Therapy assessment of bone metastatic disease in the era of 223radiumElba Etchebehere, Ana Emilia Brito, Alireza Rezaee, et al.Journal of Nuclear Medicine Technology|August 5, 2018
Validation of the Semiautomatic Quantification of 18F-Fluoride PET/CT Whole-Body Skeletal Tumor BurdenAna E Brito, Felipe Mourato, Allan Santos, et al.Radiologia Brasileira|February 27, 2019
Is interim 18F-fluoride PET/CT a predictor of outcomes after radium-223 therapy?Elba Etchebehere, Ana Emília Brito, Kalevi Kairemo, et al.Current Radiopharmaceuticals|June 30, 2018
Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution ExperienceKalevi Kairemo, Denai R Milton, Elba Etchebehere, et al.Pageof 4